In re Application of:

Wolfgang HEIL et al.

Confirmation No.: 7991

Serial No.: 09/757,688

Examiner:

L.S. Channavajjala

Filed:

January 11, 2001

Group Art Unit:

1615

Title:

DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY

# INFORMATION DISCLOSURE STATEMENT <u>UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98</u>

MAIL STOP FEE AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

### TIMING AND FEES

	<u> </u>	<u> </u>			
$\boxtimes$	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:				
		within three months of the filing date of a national application other than a CPA under § 1.53(d);			
		within three months of the actual filing date of the national phase of a PCT application; OR			
	$\boxtimes$	before the mailing of a first substantive office action (including after filing of an RCE).			
		37 C.F.R. § 1.97(c), this information disclosure statement is filed after the specified in 37 C.F.R. § 1.97(b), but before the mailing date of:			
		a final rejection under 37 C.F.R. § 1.113;			
		termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR			
		a notice of allowance under 37 C.F.R. § 1.311; and			
	is acco	mpanied by:			

	the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
	a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
	Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:
	a final action under 37 C.F.R. § 1.113;
	termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
	a notice of allowance under 37 C.F.R. § 1.311;
	AND is filed on or before payment of the issue fee; AND is accompanied by:
	the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).
STATE	EMENTS UNDER 37 C.F.R. 1.97(e)
	Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
	No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
CITED	MATERIALS
	Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).
	Copies of materials listed but not attached were cited in an international search report dated
$\boxtimes$	Copies of the materials listed are attached (except for the foregoing).
Non-I	ENGLISH LANGUAGE REFERENCES
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:

X = document of particular relevance when it is taken alone

Y = document of particular relevance when it is combined with another such document

A = document defining the general state of the art

O = non-written disclosure

P = intercalated document

T = document cited to understand the theory or principle underlying the invention

E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date

D = cited in the application

L = cited for another reason

& = publication of member of same patent family

Translation of other relevant information on foreign search report

### **OTHER INFORMATION**

## PAYMENT OF FEES DUE (IF ANY):

	A check for \$180.00 covering the fee identified above is attached.
	Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.
$\boxtimes$	The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account No. 13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

John M. Sopp, Reg. No. 33,103

Attorney for Applicants

MILLEN, WHITE, ZELANO &
BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201

Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: PLOVIN-2A

Date: April 27, 2005

JAS/slm:K:\plovin\2a\IDS & 1449.doc

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

#### Substitute for form 1449A/PTO Complete if Known 09/757,688 **Application Number INFORMATION DISCLOSURE** January 11, 2001 Filing Date STATEMENT BY APPLICANT Wolfgang HEIL et al. First Named Inventor 1615 **Group Art Unit** (use as many sheets as necessary) L.S. Channavajjala **Examiner Name** Sheet of PLOVIN-2A **Attorney Docket Number**

,			U.S. PAT	TENT DOCUMENTS		
		U.S. Patent Document				
Examiner Initials *	Cite No.1	Number	Kind Code <sup>2</sup> ( <i>if known</i> )	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
•						

	: .			FOREIGI	N PATENT DOCUMENTS	and the second second	· · · · · · · · · · · · · · · · · · ·	
Examiner Initials*	Cite No.1	Office <sup>3</sup>	oreign Patent Doci Number <sup>4</sup>	ument Kind Code <sup>5</sup> ( <i>if known</i> )	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۳°

, é		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Examiner Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine,						
		ANDA Notification by Barr Laboratories (14 pgs.)					
			١				
Examiner Signature		Date Considered					

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.